| Not Yet Recruiting | Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Gen NCT07106632 | UNICANCER | Phase 3 |
| Not Yet Recruiting | Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Ca NCT07443774 | University Hospital, Grenoble | — |
| Recruiting | Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of B NCT07233928 | Institut Claudius Regaud | N/A |
| Not Yet Recruiting | SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breas NCT07307287 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and NCT07309887 | Samsung Medical Center | — |
| Recruiting | MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC NCT07327021 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Not Yet Recruiting | SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response NCT07129187 | Chuan Wang | Phase 2 |
| Recruiting | A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study) NCT07292246 | Vasileios Kalles | N/A |
| Not Yet Recruiting | Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients NCT07101159 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursin NCT07405931 | Ulsan University Hospital | N/A |
| Withdrawn | Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in NCT06884254 | EirGenix, Inc. | Phase 3 |
| Recruiting | Mediterranean Diet and Inequality in Early Breast Cancer NCT07007169 | Esbjerg Hospital - University Hospital of Southern Denmark | Phase 2 |
| Recruiting | Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer NCT06984250 | National Taiwan University Hospital | — |
| Recruiting | Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Ca NCT06650423 | Institute of Oncology Ljubljana | — |
| Completed | An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life i NCT06690489 | Pierre Fabre Medicament | — |
| Not Yet Recruiting | Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy NCT06623903 | Aarhus University Hospital | — |
| Recruiting | Impact of "Targeted" Nutritional Apport and Exercise on the Modulation of Metabolic and Immune-related Gene Ex NCT06928701 | University of Eastern Piedmont | N/A |
| Not Yet Recruiting | Aromatherapy in the Treatment of Early Breast Cancer NCT06435104 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Not Yet Recruiting | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab NCT06371807 | Fundacao Champalimaud | Phase 2 |
| Not Yet Recruiting | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer NCT06404736 | Fudan University | Phase 2 |
| Not Yet Recruiting | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer NCT06404463 | Fudan University | Phase 2 |
| Active Not Recruiting | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2- NCT06782698 | Centro Hospitalar Universitário de Santo António | N/A |
| Recruiting | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer NCT05827081 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Can NCT06341894 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Active Not Recruiting | De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer NCT07421141 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Phase 2 |
| Completed | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Tra NCT05415215 | Hoffmann-La Roche | Phase 3 |
| Completed | Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to H NCT05217381 | MedSIR | — |
| Active Not Recruiting | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuva NCT04961996 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Canc NCT04733118 | MedSIR | Phase 2 |
| Unknown | Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer NCT04659499 | Peking Union Medical College Hospital | Phase 2 |
| Active Not Recruiting | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Pa NCT04293393 | Spanish Breast Cancer Research Group | Phase 2 |
| Withdrawn | GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel NCT04538833 | Henan Cancer Hospital | Phase 2 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With NCT04436744 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity NCT04222790 | Henan Cancer Hospital | Phase 2 |
| Recruiting | The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer NCT04291378 | Danish Breast Cancer Cooperative Group | N/A |
| Active Not Recruiting | Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Earl NCT05730647 | Consorzio Oncotech | — |
| Completed | Activity Program During Aromatase Inhibitor Therapy NCT03786198 | Swiss Cancer Institute | N/A |
| Active Not Recruiting | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients NCT03701334 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth NCT03499353 | Pfizer | Phase 2 |
| Completed | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dos NCT03493854 | Hoffmann-La Roche | Phase 3 |
| Unknown | Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer NCT03520894 | Azienda Ospedaliero-Universitaria Careggi | N/A |
| Unknown | Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubici NCT03949634 | Fudan University | Phase 3 |
| Completed | Correlation Between Tumor-infiltrating Lymphocytes and Response to Systemic Therapy in Breast Cancer NCT07404462 | Institute of Oncology Ljubljana | — |
| Completed | A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Parti NCT02738970 | Hoffmann-La Roche | Phase 1 |
| Completed | Innovative "Scoring System" in Breast Cancer Post Neoadiuvant Chemotherapy NCT05213403 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | Axillary Reverse Mapping Using Methylene Blue Subcutaneous Injection Can Identify Arm Lymph Nodes and Vessels, NCT04137744 | Zagazig University | N/A |
| Active Not Recruiting | Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer NCT02308085 | ETOP IBCSG Partners Foundation | N/A |
| Completed | A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neo NCT02187744 | Pfizer | Phase 3 |
| Terminated | A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) NCT01919229 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cance NCT01792726 | University College, London | N/A |
| Terminated | Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early NCT01155063 | Pfizer | — |
| Completed | Feasibility of Ambulatory Surgery for Early Breast Cancer NCT01613352 | Helsinki University Central Hospital | N/A |
| Completed | Arthralgia During Anastrozole Therapy for Breast Cancer NCT00323479 | AstraZeneca | Phase 4 |
| Completed | Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer NCT00713141 | National University Hospital, Singapore | — |
| Completed | Electronic Study for Anastrozole Pharmacovigilance Evaluation NCT00558168 | AstraZeneca | — |